About Angitia
Angitia is a company based in Woodland Hills (United States) founded in 2018 by Ke Huazhu. It operates as a HealthTech. Angitia has raised $406 million across 6 funding rounds from investors including Orbimed, Global Sources and Guangzhou Hi-Tech Communication Technology. Angitia offers products and services including AGA2115. Angitia operates in a competitive market with competitors including Horizon Therapeutics, AskBio, Osteal Therapeutics, Epirium Bio and ZetaGen, among others.
- Headquarter Woodland Hills, United States
- Founders Ke Huazhu
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website angitiabio.com
- Legal Name Angitia Biopharmaceuticals
- Total Equity Funding$406M (USD)
in 6 rounds
- Latest Funding Round$130M (USD), Series D
Feb 2026
- InvestorsOrbimed
& 29 more
Products & Services of Angitia
Angitia offers a comprehensive portfolio of products and services, including AGA2115.
A bispecific antibody for treating Osteogenesis Imperfecta.
Funding Insights of Angitia
Angitia has successfully raised a total of $406M across 6 strategic funding rounds. The most recent funding activity was a Series D round of $130 million completed in February 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $406M
- Total Rounds 6
- Last Round Series D — $130M
- Investors Count 30
All 6 funding rounds of Angitia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $130M | Series D | – | Frazier Life Sciences, Venrock | |
| Dec 2024 | $120M | Series C | – | Bain Capital Life Sciences | |
| Jan 2024 | $40M | Series B | – | Guangzhou Hi-Tech Communication Technology | |
| Oct 2023 | $46M | Series B | – | Morningside Venture Capital | |
| Nov 2021 | $70M | Series B | – | Morningside | |
| Aug 2020 | – | Series A | – | Hillhouse |
30 investors in total: 30 institutional.
Investors in Angitia
Angitia has secured backing from 30 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Global Sources and Guangzhou Hi-Tech Communication Technology.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | – | baincapitallifesciences.com | Boston, United States | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
- | – | yonghuacapital.com.cn | - | |
Venture Capital firm focused on multiple sectors | – | legendcapital.com.cn | Haidian, China | |
Investment in health innovation and therapies is facilitated. | – | 3hhinvestment.com | Shanghai, China | |
- | – | elikonventure.tcc.mode | - | |
- | – | guangdongcapital.tcc.mode | - | |
- | – | morningsideventurecapital.tcc.mode | - | |
- | – | aobocapital.tcc.mode | - | |
- | – | licheninvestment.tcc.mode | - |
Investor details for Angitia
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Angitia
2 people are tracked at Angitia (2 in leadership).
| Name | Role | Group |
|---|---|---|
Ke Huazhu | Founder & CEO | Leadership |
Lei Zheng | Chief Technology Officer | Leadership |
Complete people profiles for Angitia
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Angitia
3 dated milestones of Angitia across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Angitia is founded.
- Funding First funding round.
- Funding Latest funding round, Series D, of $130.0M.
Competitors of Angitia
Angitia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Horizon Therapeutics, AskBio, Osteal Therapeutics, Epirium Bio and ZetaGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| askbio.com | 2001 | Durham, United States | $235M | – | Gene and protein therapies are developed for treating various diseases. | |
| ostealtx.com | 2013 | San Clemente, United States | $110.8M | – | Developer of pharmaceuticals for musculoskeletal therapeutics to treat orthopedic infections | |
| epirium.com | 2008 | San Diego, United States | $85M | – | Therapeutic solutions for cancer via mitochondrial biogenesis are developed. | |
| zetagen.com | 2017 | Syracuse, United States | $20.35M | – | Small molecule therapeutics for bone regeneration are developed. | |
| gennao.com | 2020 | Hopewell, United States | $26M | – | Developer of nucleic acid therapeutics for cancer and rare muscular disorders | |
| satellos.com | 2012 | Toronto, Canada | $26.12M | – | Small molecule drugs for rare diseases are developed. | |
| histogenics.com | 2000 | Waltham, United States | $115.72M | 69 | Restorative cell therapies for orthopedic diseases are developed. | |
| codebiotx.com | 2020 | Hatfield, United States | $85M | – | Gene therapies for rare diseases are developed via non-viral delivery. |
Detailed competitors of Angitia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Angitia
The website of Angitia (angitiabio.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 59% vs previous month
Latest news on Angitia
Complete news archive for Angitia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Angitia
10 companies that operate in the same segment as Angitia (Orthopedics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Prosthetic and orthotic devices are developed for individuals with disabilities. | 1919 | Duderstadt, Lower Saxony, Germany | USD 17 M | USD 1.97 B | – | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of drugs for treating rare and autoimmune diseases | 2008 | Dublin, Ireland | USD 61.78 M | USD 617.41 M | – | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Robotic arms are provided for mobility and rehabilitation support. | 2004 | Boston, Massachusetts, United States | USD 17.21 M | USD 40.93 M | 185 | |
AI-powered drug discovery platform for various diseases | 2016 | New York, New York, United States | USD 608 M | – | – | |
Exoskeletons for medical rehabilitation and industrial productivity are provided. | 2005 | United States | USD 24.37 M | USD 71.6 M | 61 | |
Stabilization devices for healthcare are manufactured by the company. | 2005 | New York, New York, United States | USD 142.15 M | – | 43 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Angitia
Angitia was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Angitia is headquartered in Woodland Hills, United States. It is registered at Woodland Hills, California, United States.
Ke Huazhu is the current CEO of Angitia. They have also founded this company.
Angitia is a funded company, having raised a total of $406M across 6 funding rounds to date.
Angitia Biopharmaceuticals is engaged in the discovery and development of innovative therapeutics targeting serious musculoskeletal diseases. The company addresses unmet medical needs in conditions such as Osteogenesis Imperfecta, Osteoporosis, and Degenerative Disc Disease. Solutions are developed through clinical-stage biotechnology expertise, with a commitment to improving patient outcomes in these critical health sectors.
Angitia's top competitors include Horizon Therapeutics, AskBio and ZetaGen.
Angitia offers AGA2115.
Angitia has 30 investors. Key investors include Orbimed, Global Sources, Guangzhou Hi-Tech Communication Technology, Bain Capital Life Sciences, and Yonghua Capital.
Angitia operates through Angitia Biopharmaceuticals.